Koichi Okubo is the current CEO of CyTIX, an Immuno Oncology company that offers a combination therapy of DC/TC fusion vaccine plus hrIL-12. This therapy has gained FDA's orphan drug designation. He received his MBA in Business from the University of Southern California - Marshall School of Business and his BA in Economics from 一橋大学. Mr. Okubo has worked in several positions throughout his career, including Managing Partner at Clifford Mary, Senior Manager of the New Business Department at 株式会社ガリバーインターナショナル, Manager of Corporate Banking in Japan at Citibank N.A., Senior Vice President of PCCW in Japan, Manager of InfoCommunication & Entertainment Consulting Practice in Japan at PriceWaterhouseCoopers, and Assistant General Manager at Sumitomo Mitsui Banking Corporation.

Mr. Okubo is a seasoned executive with extensive experience in the business industry, particularly in the areas of finance and consulting. His impressive career history and educational background make him an expert in the fields of immunology, oncology, and pharmaceuticals. With his leadership skills and strategic management techniques, he has been successful in his role as the CEO of CyTIX. He is committed to achieving the mission of providing patients with the most effective therapeutic interventions possible.